期刊文献+

慢性阻塞性肺疾病合并症的研究进展 被引量:3

Research Progress in the Complications of Chronic Obstructive Pulmonary Disease
下载PDF
导出
摘要 慢性阻塞性肺疾病(COPD)不仅仅是局限于肺部的疾病,它常合并心血管疾病、糖尿病等,造成全身损害。近年来这种全身损害及合并症日益受到重视,但其产生的机制仍不清楚,目前研究认为肺部炎症溢出可能是导致全身炎性反应及产生合并症的重要原因。该文围绕COPD肺部炎症与全身炎症、合并症的关系及合并症的干预措施进行综述。 Chronic obstructive pulmonary disease(COPD) is not only confined to the lung disease, but is also often combined with cardiovascular disease, diabetes and other diseases, causing damage to the body. In recent years,its systemic damage and complications have received increasing attention, while the mechanism remains unclear,which may be associated with lung inflammation overflow leading to systemic inflammatory response com- plications. Here is to make a review of the relationship of COPD lung inflammation and systemic inflammation, and comorbidities, as well as the interventions for the complications.
出处 《医学综述》 2013年第21期3899-3901,共3页 Medical Recapitulate
基金 国家自然科学基金(81160009) 广西自然科学基金(2010GXNSFA013177)
关键词 慢性阻塞性肺疾病 全身炎症 合并症 干预措施 Chronic obstructive pulmonary disease Systemic inflammation Comorbidity Interventions
  • 相关文献

参考文献21

  • 1Vestbo J, Hurd SS, Rodriguez-Roisin R,et al. The 2011 revision ot the global strategy for the diagnosis, management and prevention of COPD(GOLD)why and what? [J].Clin Respir J,2012,6(4): 208 -214.
  • 2Nussbaumer-Ochsner Y, Rabe COPD[ J]. Chest,2011,139( 1 ) KF. Systemic manifestations of :165-173.
  • 3Gan WQ, Man SF, Senthilselvan A,et al. Association between chro- nic obstructive pulmonary disease and systemic inflammation : a sys- tematic review and a meta-analysis [ J ]. Thorax, 2004,59 ( 7 ) : 574-580.
  • 4De Tortes JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD [ J ]. Chest,2008,133 (6) : 1336-1343.
  • 5Dahl M,Vestbo J,Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease [ J ]. Am J Respir Crit Care Med,2007,175 ( 3 ) :250-255.
  • 6Casadevall C, Coronell C, Ramirez-Sarmiento AL, et al. Upregula- tion of pro-infl ammatory cytokines in the intercostal muscles of COPD patients[ J]. Eur Respir J,2007,30(4 ) :701-707.
  • 7Barnes PJ, Celli BR, Systemic manifestations and comorbidities of COPD[ J]. Eur Respir J ,2009,33 (5) : 1165-1185.
  • 8Sin DD,Leung R, Gan WQ, et al. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD : a pilot study[ J]. BMC Puhn Med,2007,7 : 13.
  • 9Barnes PJ. Chronic obstructive pulmonary disease:effects beyond the lungs [ J ]. PLoS Med,2010,7 ( 3 ) : e 1000220.
  • 10van Gestel YR, Chonchol M, Hoeks SE, et al. Association between chronic obstructive pulmonary disease and chronickidney disease in vascular surgery patients [ J ]. Nephrol Dial Transplant, 2009,24 (9) :2763-2767.

二级参考文献6

  • 1周敏,徐永健.慢性阻塞性肺疾病患者的营养支持治疗及存在的问题[J].中国实用内科杂志,2005,25(2):104-106. 被引量:54
  • 2Nici L, Donner C, Wouters E, et al. American Thoracic Society/ European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med ,2006,173 : 1390-1413.
  • 3Gosker HR, Engelen MP, van Mameren, et al. Muscle fiber type Ⅱx atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr,2002,76: 113-119.
  • 4Nici L Pulmonary rehabilitation. Proc Am Thorac Soc, 2006,3 : 66 -74.
  • 5Griffiths TL, Burr ML, Campbell IA. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet,2000,355:362-368.
  • 6Kayaban B, Karapolat H, Atyntoprak E, et aL Psychological outcomes of an outpatient pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med, 2006,100:1050-1057.

共引文献39

同被引文献54

  • 1吴纪珍,马利军,李素云,牛红丽.慢性阻塞性肺疾病发作期与缓解期体内胶原、细胞因子变化及临床意义[J].中国实用内科杂志,2005,25(8):703-704. 被引量:37
  • 2何智辉,陈平.慢性阻塞性肺疾病患者体内白介素-6和C反应蛋白质量浓度的变化及意义[J].中国实用内科杂志,2006,26(7):989-991. 被引量:50
  • 3慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 4Young J, Donahue M, Farquhar M, Simpson C, G. R. Using opioids to treat dyspnea in advanced COPD: attitudes and experiences of family physicians and respiratory therapists. Can Fam Physician, 2012,58 :e401-407.
  • 5Vestbo J,Hurd SS,R. R-R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD ( GOLD ) - why and what? Clin Respir J,2012,6:208-214.
  • 6Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med ,2007,17:532-555.
  • 7Weissenbach J, Chernajovsky Y, Zeevi M, et al. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A, 1980,77 : 7152- 7156.
  • 8Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol, 2008,101:530-535.
  • 9Quint JK, Wedzicha JA. The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immuno1,2007,119 : 1065-1071.
  • 10de Torres JP, Cordoba-Lanus E, L6pez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J ,2006,27:902-907.

引证文献3

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部